|
Synonyms: TTI-621 | TTI621
Compound class:
Peptide or derivative
Comment: Ontorpacept (TTI-621) is a 345 amino acid fusion protein that consists of the N-terminal V domain of human SIRPα fused to the Fc region of human IgG1 that was designed as an immuno-oncology agent [1]. The SIRPα domain binds to CD47 on cancer cells (to block the CD47-SIRPα anti-phagocytic signal). Inclusion of the IgG1 Fc region enhances phagocytosis of malignant cells via interaction with Fcγ receptors.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V et al.. (2017)
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res, 23 (4): 1068-1079. [PMID:27856600] |
|
2. Querfeld C, Thompson JA, Taylor MH, DeSimone JA, Zain JM, Shustov AR, Johns C, McCann S, Lin GHY, Petrova PS et al.. (2021)
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Lancet Haematol, 8 (11): e808-e817. [PMID:34627593] |
